A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in mycosis fungoides (MF)

Trial Profile

A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in mycosis fungoides (MF)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Jan 2015

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Mycosis fungoides
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 10 Mar 2014 Status changed from recruiting to discontinued as reported by ClinicalTrial.gov record.
    • 16 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top